Linked Life Data

14654945

Source:http://linkedlifedata.com/resource/pubmed/id/14654945

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-12-5
pubmed:abstractText
Anaplastic thyroid carcinoma is an aggressive neoplasm and resistant to all sorts of treatment due to its rapid growth and invasive potential. Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor modulating variety of biological properties, such as regulating of adipogenesis, inhibition of cancer cell proliferation or differentiation of tumor cells. The purpose of this study was to evaluate the possibility for the therapeutic effect of PPARgamma ligands against anaplastic thyroid tumor in vitro. Expressions of the PPARc gene and protein were examined in 5 human anaplastic carcinoma cell lines (MSA, IAA, ROA, K119 and KOA-2). We next evaluated the effects of PPARgamma ligands (Thiazolidinedione, Prostaglandin J2 and RS1303) on proliferation, differentiation, apoptosis and invasion. Five cell lines showed higher level of the PPARc gene and protein expression than papillary thyroid carcinoma. PPARgamma ligands inhibited cell proliferation by inducing apoptosis instead of differentiation in dose-dependent manner. PPARgamma ligands also down regulated the invasive potential of 5 cell lines. The inhibitory effect of proliferation or invasion was prominent in 3 cell lines, which exhibited higher expression level of the PPARc gene or protein. Our results indicated that PPARgamma ligands modify malignant potential of anaplastic carcinoma cell lines altering growth or invasive properties, suggesting that PPARgamma could be potentially the novel molecular target for human thyroid anaplastic carcinoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1019-6439
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
89-95
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:14654945-Antineoplastic Agents, pubmed-meshheading:14654945-Apoptosis, pubmed-meshheading:14654945-Blotting, Western, pubmed-meshheading:14654945-Carcinoma, pubmed-meshheading:14654945-Cell Differentiation, pubmed-meshheading:14654945-Cell Division, pubmed-meshheading:14654945-Cell Line, Tumor, pubmed-meshheading:14654945-Cell Movement, pubmed-meshheading:14654945-Dose-Response Relationship, Drug, pubmed-meshheading:14654945-Gene Expression Regulation, Neoplastic, pubmed-meshheading:14654945-Humans, pubmed-meshheading:14654945-In Situ Nick-End Labeling, pubmed-meshheading:14654945-Ligands, pubmed-meshheading:14654945-Neoplasm Invasiveness, pubmed-meshheading:14654945-Prostaglandin D2, pubmed-meshheading:14654945-RNA, Messenger, pubmed-meshheading:14654945-Receptors, Cytoplasmic and Nuclear, pubmed-meshheading:14654945-Thiazolidinediones, pubmed-meshheading:14654945-Thyroid Neoplasms, pubmed-meshheading:14654945-Transcription Factors
pubmed:year
2004
pubmed:articleTitle
Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma.
pubmed:affiliation
Department of Surgery and Clinical Oncology Graduate School of Medicine, Osaka University, Suita City, Osaka 565-0871, Japan.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't